Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PY7P | ISIN: US07373V1052 | Ticker-Symbol:
NASDAQ
04.06.25 | 21:59
17,160 US-Dollar
0,00 % 0,000
1-Jahres-Chart
BEAM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BEAM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur BEAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBeam Therapeutics Announces Orphan Drug Designation For BEAM-101180WASHINGTON (dpa-AFX) - Beam Therapeutics (BEAM) announced that the FDA has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment...
► Artikel lesen
DiBeam Therapeutics' BEAM-101 receives FDA orphan drug status for SCD treatment2
29.05.Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)913CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
► Artikel lesen
BEAM THERAPEUTICS Aktie jetzt für 0€ handeln
14.05.Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress19
12.05.Beam Therapeutics granted FDA's Regenerative Medicine Advanced Therapy designation2
12.05.Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)245CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
► Artikel lesen
07.05.10 Analysts Assess Beam Therapeutics: What You Need To Know6
06.05.Why Beam Therapeutics Stock Tanked on Tuesday5
06.05.Beam Therapeutics GAAP EPS of -$1.24 misses by $0.05, revenue of $7.47M misses by $7.21M5
06.05.Beam Therapeutics Inc. - 10-Q, Quarterly Report2
06.05.Beam Therapeutics Inc. Q1 Loss Increases, Misses Estimates294WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for its first quarter that increased from last year and missed the Street estimates.The company's bottom line totaled -$109.27...
► Artikel lesen
06.05.Beam Therapeutics Inc. - 8-K, Current Report3
25.04.Beam Therapeutics to Report Q1 Earnings: What's in the Cards?6
25.04.Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock9
11.04.Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock40
07.04.Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease3
31.03.Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard40
28.03.Beam Therapeutics-Aktie steigt nach FDA-Zulassung für BEAM-302 IND14
28.03.Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND4
28.03.Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock2
Seite:  Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1